Effect of the methylenetetrahydrofolate reductase gene C677T polymorphism on C-erbB-2 methylation status and its association with cancer

Molecular Medicine Reports

Volumn 2, Issue 2, 2009, Pages 283-289

  Jin, Zhonggan ^a   Lu, Qing ^a   Ge, Danhong ^a   Zong, Ming ^b   Zhu, Qinghui ^a  

^a JIANGSU UNIVERSITY   (China)

^b Key Laboratory of Arrhythmias of Ministry of Education   (China)

Author keywords

C erbB 2; Cancer; Methylation; Methylenetetrahydrofolate reductase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CLINICAL FEATURE; CONTROLLED STUDY; CPG ISLAND; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METHYLATION; ONCOGENE; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

EID: 69249083228     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_00000097     Document Type: Article

References (32)

1. Baylin SB and Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16: 168-174, 2000.
2. Ehrlich M: DNA methylation in cancer: too much, but also too little. Oncogene 21: 5400-5413, 2002.
3. Choi SW and Mason JB: Folate and carcinogenesis: an integrated scheme. J Nutr 130: 129-132, 2000.
4. Friso S, Choi SW, Girelli D, et al: A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci USA 99: 5606-5611, 2002. (Pubitemid 34411596)
5. Frosst P, Blom HJ, Milos R, et al: A candidate genetic risk factor for vascular disease: a common mutation in methylene-tetrahydrofolate reductase. Nat Genet 10: 111-113, 1995.
6. Sharp L and Little J: Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am J Epidemiol 159: 423-443, 2004. (Pubitemid 38280289)
7. Franco RF, Simões BP, Tone LG, Gabellini SM, Zago MA and Falcão RP: The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukaemia. Br J Haematol 115: 616-618, 2001.
8. Yin G, Kono S, Toyomura K, et al: Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and colorectal cancer: the Fukuoka Colorectal Cancer Study. Cancer Sci 95: 908-913, 2004. (Pubitemid 40045526)
9. Suzuki T, Matsuo K, Hiraki A, et al: Impact of one-carbon metabolism-related gene polymorphisms on risk of lung cancer in Japan: a case control study. Carcinogenesis 28: 1718-1725, 2007. (Pubitemid 47303945)
10. Suzuki T, Matsuo K, Hirose K, et al: One-carbon metabolism-related gene polymorphisms and risk of breast cancer. Carcinogenesis 29: 356-362, 2008. (Pubitemid 351359675)
11. Dong LM, Potter JD, White E, Ulrich CM, Cardon LR and Peters U: Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 299: 2423-2436, 2008. (Pubitemid 351749241)
12. Song C, Xing D, Tan W, Wei Q and Lin D: Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res 61: 3272-3275, 2001. (Pubitemid 32695011)
13. Zhang XM, Miao XP, Tan W, Qu SN, Sun T, Zhou YF and Lin DX: Association between genetic polymorphisms in methylentetrahydrofolate reductase and risk of lung cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 27: 700-703, 2005.
14. Kim JK, Kim S, Han JH, et al: Polymorphisms of 5,10-methylene- tetrahydrofolate reductase and risk of stomach cancer in a Korean population. Anticancer Res 25: 2249-2252, 2005. (Pubitemid 40904630)
15. Hekim N, Ergen A, Yaylim I, Yilmaz H, Zeybek U, Oztürk O and Isbir T: No association between methylenetetrahydrofolate reductase C677T polymorphism and breast cancer. Cell Biochem Funct 25: 115-117, 2007. (Pubitemid 46127360)
16. Clarizia AD, Bastos-Rodrigues L, Pena HB, et al: Relationship of the methylenetetrahydrofolate reductase C677T polymorphism with microsatellite instability and promoter hypermethylation in sporadic colorectal cancer. Genet Mol Res 5: 315-322, 2006. (Pubitemid 43991970)
17. Kang S, Kim JW, Kang GH, Park NH, Song YS, Kang SB and Lee HP: Polymorphism in folate- and methionine-metabolizing enzyme and aberrant CpG island hypermethylation in uterine cervical cancer. Gynecol Oncol 96: 173-180, 2005. (Pubitemid 39612433)
18. Oyama K, Kawakami K, Maeda K, Ishiguro K and Watanabe G: The association between methylenetetrahydrofolate reductase polymorphism and promoter methylation in proximal colon cancer. Anticancer Res 24: 649-654, 2004. (Pubitemid 38625002)
19. Bargmann CI, Hung MC and Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319: 226-230, 1986. (Pubitemid 16128785)
20. Kim MA, Jung EJ, Lee HS, Lee HE, Jeon YK, Yang HK and Kim WH: Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 38: 1386-1393, 2007.
21. Wülfing C, von Struensee D, Bierer S, Bögemann M, Hertle L and Eltze E: Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy. Aktuelle Urol 36: 423-429, 2005. (Pubitemid 41411615)
22. Tavangar SM, Shariftabrizi A and Soroush AR: Her-2/neu overexpression correlates with more advanced disease in Iranian colorectal cancer patients. Med Sci Monit 11: CR123-CR126, 2005. (Pubitemid 40445984)
23. Yu D and Hung MC: Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19: 6115-6121, 2000. (Pubitemid 32059461)
24. Hattori M, Sakamoto H, Satoh K and Yamamoto T: DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett 169: 155-164, 2001. (Pubitemid 32595563)
25. Holzmann K, Welter C, Klein V, Pistorius G, Seitz G and Blin N: Tumor-specific methylation patterns of erbB2 (HER2/neu) sequences in gastro-intestinal cancer. Anticancer Res 12: 1013-1018, 1992.
26. Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996. (Pubitemid 26296693)
27. Paredes J, Albergaria A, Oliveira JT, Jerónimo C, Milanezi F and Schmitt FC: P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 11: 5869-5877, 2005. (Pubitemid 41170315)
28. Oshimo Y, Nakayama H, Ito R, Kitadai Y, Yoshida K, Chayama K and Yasui W: Promoter methylation of cyclin D2 gene in gastric carcinoma. Int J Oncol 23: 1663-1670, 2003.
29. Akiyama T, Sudo C, Ogawara H, Toyoshima K and Yamamoto T: The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232: 1644-1646, 1986. (Pubitemid 16095607)
30. Robertson KD: DNA methylation and human disease. Nat Rev Genet 6: 597-610, 2005.
31. Bailey LB: Folate, methyl-related nutrients, alcohol, and the MTHFR 677C→T polymorphism affect cancer risk: intake recommendations. J Nutr 133: 3748S-3753S, 2003.
32. Paz MF, Avila S, Fraga MF, et al: Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer 62: 4519-4524, 2002.